- Daraasadda CDC ee Kormeerka Badbaadada ee Qiyaasta Dheeraadka ah ee Tallaalka COVID-19
- Waxa hore looga yaqaanay thama tallaalka xoojiyaha?
- Ka mid ah 306 kaqeybgaleyaasha tijaabada caafimaad ee Pfizer-BioNTech, falcelinta xun kadib qiyaasta 3 waxay la mid tahay kuwa kadib qiyaasta 2.
Maxaa lagu daray warbixintan lambarka toogashada 3 ee ay sii deysay CDC maanta?
Intii lagu jiray Ogosto 12-Sebtember 19, 2021, oo ka mid ah 12,591 diiwaan-geliyeyaal v-safe ah oo dhammaystiray sahan baaritaan caafimaad ka dib dhammaan 3 qiyaasood oo ah tallaalka mRNA COVID-19, 79.4% iyo 74.1% ayaa soo sheegay falcelinno maxalli ah ama nidaamsan, siday u kala horreeyaan, qiyaasta saddexaad; 77.6% iyo 76.5% ayaa soo sheegay falcelinta maxalliga ah ama nidaamsan kadib qiyaastii labaad, siday u kala horreeyaan.
Maxay yihiin saameynta caafimaadka ee dadweynaha?
Warbixinada iskaa wax u qabso ee v-safe ma helin qaabab lama filaan ah oo falcelin xun kadib qiyaas dheeri ah oo tallaalka COVID-19 ah. CDC waxay sii wadi doontaa la socoshada badbaadada tallaalka, oo ay ku jirto qiyaaso dheeraad ah oo COVID-19 ah.
Ogosto 12, 2021, Maamulka Cuntada iyo Dawooyinka (FDA) ayaa wax ka beddelay Ruqsadaha Isticmaalka Degdegga ah (EUAs) ee tallaallada Pfizer-BioNTech iyo Moderna COVID-19 si ay u oggolaadaan maamulka qaddar dheeri ah kadib dhammaystirka taxanaha tallaalka koowaad ee dadka u qalma xaaladaha difaaca jirka oo dhexdhexaad ah ama daran (1,2). Bishii Sebtember 22, 2021, FDA waxay oggolaatay qaddar dheeri ah oo ah tallaalka Pfizer-BioNTech months6 bilood ka dib dhammaystirka taxanaha koowaad ee dadka da'doodu tahay ≥65 sano, oo halis weyn ugu jira COVID-19 daran, ama soo-gaadhistooda xirfadeed ama hay'ad ay geliso khatarta sare u leh COVID-19 (1). Natiijooyinka ka soo baxay tijaabo caafimaad oo weji 3 ah oo ay samaysay Pfizer-BioNTech oo ay ku jiraan 306 qof oo da'doodu u dhaxayso 18-55 sano ayaa muujisay in falcelinta xun ka dib markii la helay qaddar saddexaad oo la maamulay 5-8 bilood kadib dhammaystirka 2-qiyaasta taxanaha tallaalka aasaasiga ah ee mRNA waxay la mid yihiin kuwa la soo sheegay ka dib markii la helay qaddarka 2; falcelintaan xun waxaa ka mid ah goob duritaan dhexdhexaad ah ilaa dhexdhexaad ah iyo falcelin nidaamsan (3). CDC waxay soo saartay v-safe, ikhtiyaari ah, nidaam ilaalin badbaado oo ku saleysan taleefanka gacanta, si loo bixiyo macluumaad ku saabsan falcelinta xun kadib tallaalka COVID-19.
Si lama filaan ah oggolaanshaha qaddar dheeri ah oo loogu talagalay dadka qaba xaaladaha ka-hortagga, mashiinka v-safe ayaa la cusbooneysiiyay si loogu oggolaado is-diiwaangeliyayaasha inay galaan macluumaadka ku saabsan qiyaaso dheeraad ah oo tallaalka COVID-19 ah oo la helay. Intii lagu guda jiray Ogosto 12-Sebtember 19, 2021, wadar ahaan 22,191 diiwaan-geliyeyaal ammaan-suge ah ayaa soo sheegay inay heleen qadar dheeri ah oo tallaalka COVID-19 ah. Intooda badan (97.6%) waxay soo sheegeen taxane tallaal mRNA oo ah 2-qiyaasood oo xigay qaddar saddexaad oo isla tallaalka ah. Ka mid ah kuwa dhammaystiray sahanka is-hubinta caafimaadka ee dhammaan 3 qiyaasood (12,591; 58.1%), 79.4% iyo 74.1% ayaa soo sheegay falcelinta maxalliga ah ama nidaamsan, siday u kala horreeyaan, qiyaasta 3 kadib, marka la barbar dhigo 77.6% iyo 76.5% oo soo sheegay deegaanka ama nidaamka falcelinta, siday u kala horreeyaan, ka dib qiyaasta 2. Natiijooyinkan bilowga ahi ma muujinayaan qaabab aan la filayn oo falcelin-xumo ah ka dib qiyaas dheeri ah oo tallaalka COVID-19; inta badan falcelintan xun waxay ahaayeen kuwo fudud ama dhexdhexaad ah. CDC waxay sii wadi doontaa la socoshada badbaadada tallaalka, oo ay ku jirto badbaadada qiyaaso dheeri ah oo tallaalka COVID-19 ah, waxayna bixin doontaa xog hagta talooyinka tallaalka iyo ilaalinta caafimaadka dadweynaha.
V-safe waa hab ikhtiyaari ah, oo ku salaysan taleefanka casriga ah ee nidaamka ilaalinta Maraykanka; dadka la tallaalay ee u qalma inay helaan alaabta tallaalka ee idman ama ruqsad haysta ayaa iska diiwaangelin kara v-safe. Madasha v-safe waxay u oggolaanaysaa diiwaangeliyayaasha jira inay soo sheegaan helitaanka qadar dheeri ah oo tallaalka COVID-19 ah iyo diiwaan-geliyeyaasha cusub inay galaan macluumaadka ku saabsan dhammaan qiyaasaha tallaalka COVID-19 ee la helay. Baadhitaanada caafimaadka ee V-nabdoon ayaa la diraa inta lagu jiro maalmaha 0–7 kadib qiyaas kasta oo tallaal ah waxaana ku jira su'aalo ku saabsan goobta duritaanka ee deegaanka iyo falcelinta habdhiska iyo saamaynta caafimaadka.† Xubnaha shaqaalaha ee Nidaamka Warbixinta Dhacdada Dhacdada Tallaalka (VAERS) waxay la xiriiraan diiwaan -geliyeyaasha oo tilmaamaya in daryeel caafimaad la raadiyay tallaalka kaddibna dhiirri -geliyo ama fududeeyo dhammaystirka warbixinta VAERS, haddii la tilmaamo.§
Diiwaangeliyeyaasha v-safe-ka ah ee ka warbixiyay helitaanka tallaalka COVID-19 oo dheeri ah intii lagu jiray Ogosto 12-Sebtember 19, 2021, xogta dadweynaha, falcelinta maxalliga ah iyo nidaamyada, iyo saamaynta caafimaad ee la soo sheegay maalmaha 0–7 ayaa lagu sifeeyay qaabka tallaalka (ie , soo -saaraha tallaalka oo la siiyay qiyaas kasta). Dadka soo sheegay inay ka heleen taxane asaasi ah soo-saareyaal kala duwan ama soo-saare aan la garanayn ama aan laga heli karin Maraykanka, ama 2 qiyaasood oo tallaal ah ka dib markii la siiyay Janssen (Johnson & Johnson) tallaal hal-qaadasho ah (150) ayaa laga saaray falanqaynta ee falcelinta xun kadib marka la helo qiyaasta dheeraadka ah.
Waqtigu wuu dhammaaday markii la dhammaystiray taxanaha tallaalka asaasiga ah illaa helitaanka qaddar dheeri ah ayaa lagu sifeeyay qaabka tallaalka. Qeexitaannada dhacdooyinka xun kadib qiyaasaha 2 iyo 3 ayaa loo barbardhigay diiwaan -geliyeyaasha ka helay tallaalka mRNA isla soo -saare dhammaan saddexda qiyaasood.¶ Software -ka SAS (nooca 9.4; Machadka SAS) ayaa loo isticmaalay in lagu sameeyo dhammaan falanqaynta. Hawlahan dabagalka waxaa dib u eegay CDC waxaana loo sameeyay si waafaqsan sharciga federaalka ee khuseeya iyo siyaasadda CDC. **
Intii lagu guda jiray Ogosto 12-Sebtember 19, 2021, wadar ahaan 22,191 diiwaan-geliyeyaasha v-safe ayaa sheegay inay heleen qadar dheeri ah oo tallaalka COVID-19 ah markay dhammaystireen taxanaha koowaad (Shaxda 1). Kuwaas waxaa ka mid ah, 14,048 (63.3%) waxay ahaayeen dheddig, qiyaastii 30% midkiiba wuxuu jiray 18–49, 50–64, iyo 65–74 sano.
Diiwaangeliyeyaasha badankood (21,662; 97.6%) ayaa soo sheegay in ay ka heleen qiyaas saddexaad oo isla soo-saare ah sida taxanaha tallaalka mRNA ee ugu horreeya, oo ay ku jiraan 98.6% qaatayaasha Moderna iyo 98.2% ee qaatayaasha Pfizer-BioNTech. Diiwaangeliyeyaasha tiro yar (341; 1.5%) ayaa soo sheegay taxanaha tallaalka mRNA ee ugu horreeya oo ay ku xigto qadar dheeri ah oo tallaalka mRNA ah oo ka yimid soo -saare kale, qiyaas tallaalka Janssen ka dib markii la helay taxanaha tallaalka mRNA ee ugu horreeya (10; 0.05%), ama mid dheeri ah qiyaasta tallaalka COVID-19 oo laga helo soo-saare kasta ka dib tallaalka Janssen (178; 0.8%).
Waxaa ka mid ah 22,191 diiwaan-geliyayaal badbaado-leh, dhex-dhexaadka laga bilaabo dhammaystirka taxanaha tallaalka COVID-19 ee ugu horreeya illaa helitaanka qaddar dheeri ah wuxuu ahaa 182 maalmood (kala-dhex-dhexaad [IQR] = 160–202 maalmood) (Shaxda 2). Ka mid ah kuwa qaatay 2 qiyaasood oo ah tallaalka Janssen, dhex -dhexaadka u dhexeeya qaadashadu wuu yaraa (84 maalmood; IQR = 16–136 maalmood).
Maxalliga ah (16,615; 74.9%) iyo hab-raacyada (15,503; 69.9%) ayaa si joogto ah loo soo sheegaa inta lagu jiro usbuuca ka dib markii la qaatay qadar dheeri ah oo tallaalka COVID-19, badiyaa maalinta tallaalka kadib. Dareen -celinta inta badan la soo sheego waxay ahaayeen xanuun goobta duritaan (15,761; 71.0%), daal (12,429; 56.0%), iyo madax -xanuun (9,636; 43.4%).
22,191 ka mid ah dadka qaata qiyaasta dheeraadka ah, wadar ahaan 7,067 (31.8%) ayaa soo sheegay saamaynta caafimaad, iyo qiyaastii 28.3% (6,287) ayaa sheegay inaysan awoodin inay qabtaan hawl maalmeed caadi ah, badiyaa maalinta tallaalka kadib. Daryeelka caafimaad waxaa raadiyey 401 (1.8%) diiwaan -geliyeyaasha, saddex iyo toban (0.1%) ayaa isbitaal la dhigay. Sababaha loo helo daryeel caafimaad ama isbitaal laguma sheegin sahanka v-safe; si kastaba ha ahaatee, diiwaan -geliyeyaasha tilmaamaya in daryeel caafimaad la raadiyay tallaalka ka dib ayaa ay la soo xiriiraan shaqaalaha VAERS waxayna ku dhiirri -geliyaan inay dhammaystiraan warbixinta VAERS.
Ka mid ah 21,658 diiwaangeliyeyaasha v-safe-ka ah ee qaatay isla tallaalka mRNA ee dhammaan 3 qiyaasood, 12,591 (58.1%) ayaa dhammaystiray ugu yaraan hal sahan baaritaan caafimaad maalmaha 0–7 ka dib dhammaan 3dii qiyaasood; 79.4% iyo 74.1% ayaa soo sheegay falcelinta maxalliga ah ama nidaamsan, siday u kala horreeyaan, kadib qiyaasta 3, marka la barbar dhigo 77.6% iyo 76.5% kuwaas oo soo sheegay falcelinta maxalliga ah ama nidaamsan, siday u kala horreeyaan, ka dib qiyaasta 2. Ka mid ah diiwaan -geliyeyaasha helay 3 qiyaasood ee Moderna (6,283), maxalliga ah Dareen-celinta ayaa la soo sheegay marar badan kadib qiyaasta 3 marka loo eego qiyaasta 2 (5,323; 84.7% iyo 5,249; 83.5%; p-value = 0.03) (Jaantuska). Dareen-celinta hab-dhismeedka ayaa si yar loo soo sheegay ka dib qiyaasta 3 marka loo eego qiyaasta 2 (4,963; 79.0% iyo 5,105; 81.3%; p-value <0.001).
Diiwaangeliyeyaasha helay 3 qiyaasood ee Pfizer-BioNTech (6,308), falcelinta maxalliga ayaa la soo sheegay marar badan kadib qiyaasta 3 marka loo eego qiyaasta 2 (4,674; 74.1% iyo 4,523; 71.7%; p-value <0.001). Dareen-celinta hab-dhismeedka ayaa si yar loo soo sheegay ka dib qiyaasta 3 marka loo eego qiyaasta 2 (4,363; 69.2% iyo 4,524; 71.7%; p-value <0.001). Ka mid ah kuwa soo sheegay xanuunka ka dib qiyaasta 3 ee tallaalka mRNA, falcelinta badidoodu waxay ahayd mid fudud (4,909; 51.4%) ama dhexdhexaad (4,000; 41.9%); xanuun daran (oo lagu qeexay xanuun ka dhigaya hawl maalmeedka mid adag ama aan suurogal ahayn) waxaa soo sheegay 637 (6.7%).
Dood
Laga bilaabo Sebtember 19, 2021, qiyaastii 2.21 milyan oo qof oo ku nool Mareykanka ayaa qaatay qiyaaso dheeraad ah oo ah tallaallada COVID-19†† kadib marka la dhamaystiro taxanaha koowaad. Laga soo bilaabo Ogosto 12-Sebtember 19, 2021, ma jirin qaabab lama filaan ah oo falcelin xun lagu arkay 22,191 diiwaan-geliyeyaal ammaan-qaba oo qaatay qaddar dheeraad ah tallaalka COVID-19. Falcelinnada maxalliga ah iyo kuwa nidaamsan ee inta badan la soo sheegay waxay ahaayeen kuwo fudud ilaa dhexdhexaad ah, ku -meel -gaadh ah, oo inta badan la soo sheegay maalinta tallaalka kadib. Diiwaangeliyeyaasha intooda badan la siiyay qaddar dheeri ah waxay soo sheegeen taxanaha tallaalka mRNA ee ugu horreeya oo ay ku xigto qiyaas saddexaad oo isla soo -saare ah.
Tijaabada caafimaad ee Pfizer-BioNTech, oo ay ku jiraan 306 qof oo da'doodu u dhaxayso 18-55 sano, ayaa muujisay in falcelinta kadib qiyaasta 3 ay u dhigantaa kuwa la soo sheegay kadib qiyaasta 2 (3). Si kastaba ha ahaatee, falanqayntan xogta v-nabdoon ayaa lagu ogaaday in falcelinta maxalliga ahi ay aad u yaraayeen isla markaana falcelinnada nidaamku aad u yaraayeen kadib qiyaasta 3 ee Pfizer-BioNTech.
Qaababka falcelinta xun ee la arkay kadib qiyaasta 3 ee tallaalka Moderna ama Pfizer-BioNTech waxay la socdeen falcelintii hore loo sharraxay ka dib markii la helay qaddarka 2
Tirada diiwaan -geliyeyaasha ee tilmaamay inay heleen 2 qiyaasood oo tallaalka Janssen ah ama ay ka qaateen qaddarkooda dheeraadka ah soo -saare ka duwan kan taxaddarradooda koowaad ayaa ahaa mid yar, taasoo xaddidaysa wixii gunaanad ah.
Xogta ku saabsan badbaadada ama waxtarka tallaalka ee alaabta tallaalka COVID-19 ee soo-saarayaasha kala duwan ayaa xaddidan; Guddiga La-talinta ee Ku-Dhaqanka Tallaalka (ACIP) waxay ku talinayaan in dadka qaba xaalado difaac-dhexdhexaad ah oo aad u daran ay ka helaan qiyaasta saddexaad ee tallaalka mRNA COVID-19 isla soo-saaraha sida taxanahooda koowaad.
Talooyinka CDC ee qaddar dheeraad ah hadda kuma jiraan dadka qaatay tallaalka Janssen.
Intii lagu jiray muddadii ay daraasaddani daboolaysay, talooyinka ACIP ee tallaalka dheeraadka ah ee tallaalka COVID-19 waxay ku koobnaayeen dadka dhexdhexaadka ah ilaa xaaladaha daran ee difaaca jirka ee helay
2 qiyaasood oo tallaalka mRNA ah.
Daraasad lagu sameeyay bukaan-socodka dhiig-yaraanta difaaca jirka ayaa soo sheegay in falcelinta maxalliga ah iyo kuwa nidaamsan kadib qiyaasta 3 ee tallaalka Pfizer-BioNTech ay la mid yihiin kuwa kadib qiyaasta 2.¶¶ Warbixinadii u dambeeyay ee caabuqyada dadka la tallaalay iyo korodhka baahsanaanta caabuqa ee leh B.1.617.2 (Delta) kala duwanaanshaha SARS-CoV-2, fayraska sababa COVID-19, ee ka dhex jira dadka la tallaalay ayaa laga yaabaa inuu ku kallifay dadka qaar inay raadsadaan qiyaas dheeraad ah oo ka baxsan talooyinka. Inta u dhaxaysay laga soo bilaabo dhamaystirka taxanaha aasaasiga ah ilaa helitaanka qiyaas dheeraad ah waxay ahayd qiyaastii 6 bilood; sidaas darteed, dadka mudnaanta la siiyay inta lagu guda jiro faafinta tallaalka COVID-19, oo ay ku jiraan shaqaalaha daryeelka caafimaadka iyo dadka waaweyn, ayaa laga yaabaa inay heleen qiyaas dheeraad ah.
Natiijooyinka warbixintan waxay ku xiran yihiin ugu yaraan afar xaddidaad. Marka hore, isqorista v-safe waa ikhtiyaari waxayna u badan tahay inaysan wakiil ka ahayn dadka la tallaalay ee Mareykanka; inta badan ka qaybgalayaashu waxay isu aqoonsadeen inay yihiin Caddaan iyo Isbaanish. Midda labaad, muddada daraasaddan, talooyinka qaddarinta dheeraadka ah waxay ku koobnaayeen dadka qaba xaalado difaaca jirka oo dhammaystiray taxanaha tallaalka mRNA COVID-19; hase yeeshee, v-safe kuma jiraan macluumaad ku saabsan xaaladda difaaca.
Dadka qaata qiyaasta dheeraadka ah waxay u badan tahay inay ku jiraan dad qaba ama aan lahayn xaalado difaaca jirka. Saddexaad, xiriirka sababaha ka dhexeeya tallaalka iyo dhacdooyinka xun ee kiliinikada ah ee la soo sheegay kadib tallaalka lama samayn karo iyadoo la isticmaalayo xogta v-safe. Ugu dambayntii, xog aan ku filnayn ayaa la heli karay si loo go'aamiyo qaababka falcelinta xun kadib markii laga helay qaddar dheeri ah soo -saare ka duwan taxanaha koowaad ama tallaalka Janssen.
Qiyaas dheeri ah oo tallaalka mRNA COVID-19 ayaa lagula talinayaa dadka qaba xaalado difaaca jirka oo dhexdhexaad ah ama aad u daran (5).
CDC waxay ku talisay in la siiyo qadar dheeri ah oo tallaalka Pfizer-BioNTech months6 bilood kadib markii la dhammaystiray taxanaha tallaalka asaasiga ah ee dadka jira ≥65 sano, dadka deggan goobaha daryeelka muddada-dheer, iyo dadka da'doodu u dhaxayso 50-64 sano oo qaba xaalado caafimaad oo hoose; dadka da'doodu u dhaxayso 18-49 sano oo qaba xaalado caafimaad oo hoose iyo dadka da'doodu u dhaxayso 18-64 sano oo halis ugu jira soo-gaadhista iyo gudbinta COVID-19 sababtuna tahay goob shaqo ama hay'ad ayaa laga yaabaa inay helaan qaddar dheeraad ah oo ku salaysan faa'iidooyinkooda iyo halista shaqsiyeed
Falanqaynta bilowga ah ee xogta badbaadada ee ka timid> 22,000 diiwaan-geliyeyaasha badbaadada v-ammaan ah ayaa muujinaya in falcelinta maxalliga ahi xoogaa kordhay oo falcelinnada nidaamku ay yara yaraadeen kadib qiyaasta 3 ee mRNA marka loo eego qiyaasta 2.
Ma jirin qaabab lama filaan ah oo falcelin xun; kuwa la soo sheegay waxay ahaayeen kuwo fudud ilaa dhexdhexaad iyo ku -meelgaar. CDC waxay sii wadi doontaa la socodka badqabka qiyaasaha dheeraadka ah ee tallaalka COVID-19. Xog dheeri ah oo ku saabsan falcelinta xun ee la xiriirta isku -darka kala duwan ee tallaallada iyo waqtiga tan iyo dhammaystirka taxanaha asaasiga ah ayaa muhiim u noqon doonta hagitaanka talooyinka caafimaadka dadweynaha.
| caan | Moderna, %† (n=10,601) | Pfizer-BioNTech, %† (n=11,412) | Janssen, %†, § (n=178) | Wadarta Guud (N = 22,191) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Qiyaasta 3 Moderna (n = 10,453; 98.6%) | Qiyaasta 3 Pfizer-BioNTech (n = 144; 1.4%) | Qiyaasta 3 Janssen (n = 4; 0.04%) | Qiyaasta 3 Pfizer-BioNTech (n = 11,209; 98.2%) | Qiyaasta 3 Moderna (n = 197; 1.7%) | Qiyaasta 3 Janssen (n = 6; 0.1%) | Qiyaasta 2 Janssen (n = 48; 27.0%) | Qiyaasta 2 Moderna (n = 64; 36.0%) | Qiyaasta 2 Pfizer-BioNTech (n = 66; 37.1%) | ||
| Sex | ||||||||||
| Female | 63.8 | 63.9 | 50.0 | 63.0 | 63.5 | 33.3 | 39.6 | 57.8 | 59.1 | 63.3 |
| Male | 35.1 | 34.0 | 50.0 | 36.1 | 36.0 | 66.7 | 60.4 | 42.2 | 40.9 | 35.7 |
| Unknown | 1.0 | 2.1 | 0 | 0.9 | 0.5 | 0 | 0 | 0 | 0 | 1.0 |
| Kooxda da'da, sanadaha | ||||||||||
| 0-17 | 0.0 | 0.7 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| 18-49 | 25.7 | 36.1 | 25.0 | 31.5 | 42.6 | 50.0 | 54.2 | 60.9 | 57.6 | 29.1 |
| 50-64 | 28.4 | 27.1 | 50.0 | 31.1 | 29.9 | 0.0 | 33.3 | 34.3 | 30.3 | 29.8 |
| 65-74 | 33.9 | 27.1 | 0.0 | 27.8 | 21.3 | 50.0 | 10.4 | 4.7 | 9.1 | 30.5 |
| 75-84 | 10.9 | 9.0 | 25.0 | 8.3 | 5.6 | 0.0 | 2.1 | 0.0 | 3.0 | 9.5 |
| ≥85 | 1.1 | 0.0 | 0.0 | 0.7 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 |
| Asalka | ||||||||||
| Hispanic / Latino | 8.0 | 15.3 | 0 | 8.2 | 5.6 | 0 | 25.0 | 6.3 | 10.6 | 8.2 |
| Isbaanish/Laatiin | 87.7 | 81.9 | 100 | 87.6 | 90.9 | 100 | 54.2 | 89.1 | 89.4 | 87.6 |
| Unknown | 4.3 | 2.8 | 0 | 4.2 | 3.6 | 0 | 20.8 | 4.7 | 0 | 4.2 |
| Race | ||||||||||
| AI/AN | 0.5 | 0.7 | 0 | 0.5 | 0.5 | 0 | 2.1 | 0 | 0 | 0.5 |
| Asian | 4.9 | 5.6 | 0 | 6.1 | 7.1 | 0 | 2.1 | 14.1 | 13.6 | 5.6 |
| Black | 5.6 | 3.5 | 0 | 6.2 | 1.5 | 16.7 | 6.3 | 6.3 | 9.1 | 5.9 |
| NHPI | 0.2 | 0 | 0 | 0.3 | 0.5 | 0 | 4.2 | 0 | 0 | 0.3 |
| White | 82.6 | 82.6 | 100 | 80.4 | 85.8 | 66.7 | 56.3 | 71.9 | 69.7 | 81.4 |
| Dhaqan badan | 1.9 | 2.1 | 0 | 1.8 | 1.5 | 16.7 | 4.2 | 4.7 | 3.0 | 1.9 |
| kale | 2.1 | 4.2 | 0 | 2.1 | 0.5 | 0 | 6.3 | 1.6 | 3.0 | 2.1 |
| Unknown | 2.3 | 1.4 | 0 | 2.5 | 2.5 | 0 | 18.8 | 1.6 | 1.5 | 2.4 |
Gaabashooyinka: AI/AN = Hindida Maraykanka/Dhaladka Alaska; NHPI = Native Hawaiian ama Jasiirad kale oo Baasifik ah.
* Boqolleyda diiwaangeliyeyaasha ee dhammaystiray ugu yaraan hal sahan-hubin caafimaad oo v-ammaan ah maalmaha 0–7 tallaalka kadib.
† Taxanaha tallaalka koowaad.
§ Waxaa ku jira dadka qaatay Janssen oo ah hal-qaadasho iyo 1 tallaal oo dheeraad ah oo ka yimid soo-saarayaasha liistada.
| Reaction | Moderna, %† (n=10,477) | Pfizer-BioNTech, %† (n=11,284) | Janssen, %†, § (n=174) | Wadarta Guud (N = 22,191) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Qiyaasta 3 Moderna (n = 10,453; 98.6%) | Qiyaasta 3 Pfizer-BioNTech (n = 144; 1.4%) | Qiyaasta 3 Janssen (n = 4; 0.04%) | Qiyaasta 3 Pfizer-BioNTech (n = 11,209; 98.2%) | Qiyaasta 3 Moderna (n = 197; 1.7%) | Qiyaasta 3 Janssen (n = 6; 0.1%) | Qiyaasta 2 Janssen (n = 48; 27.0%) | Qiyaasta 2 Moderna (n = 64; 36.0%) | Qiyaasta 2 Pfizer-BioNTech (n = 66; 37.1%) | ||
| Maalmo laga bilaabo taxanaha koowaad, dhexdhexaad (IQR) | 182 (164-198) | 183 (161-204) | 173 (141-182) | 183 (157-209) | 186 (161-217) | 123 (113-182) | 84 (16-136) | 156 (140-164) | 150 (136-167) | 182 (160-202) |
| Falcelin kasta oo goobta duritaan ah | 80.9 | 64.6 | 75.0 | 69.4 | 81.7 | 83.3 | 25.0 | 70.3 | 80.3 | 74.9 |
| Cuncun | 20.0 | 11.8 | 0 | 8.4 | 10.2 | 16.7 | 10.4 | 6.3 | 7.6 | 13.9 |
| Xanuun | 75.9 | 60.4 | 75.0 | 66.6 | 80.2 | 83.3 | 20.8 | 68.8 | 74.2 | 71.0 |
| Casaan | 25.2 | 8.3 | 0 | 9.8 | 20.8 | 16.7 | 6.3 | 7.8 | 12.1 | 17.1 |
| Barar | 33.6 | 17.4 | 0 | 16.8 | 30.5 | 16.7 | 6.3 | 12.5 | 18.2 | 24.8 |
| Falcelin kasta oo nidaamsan | 75.2 | 59.7 | 50.0 | 65.1 | 76.1 | 100 | 31.3 | 68.8 | 63.6 | 69.9 |
| Calool xanuun | 8.4 | 3.5 | 0 | 6.4 | 8.1 | 16.7 | 4.2 | 3.1 | 6.1 | 7.3 |
| Myalgia | 49.8 | 29.2 | 0 | 36.3 | 49.2 | 50.0 | 20.8 | 45.3 | 33.3 | 42.7 |
| Qarxo | 31.3 | 8.3 | 50.0 | 17.5 | 33.5 | 50.0 | 8.3 | 23.4 | 10.6 | 24.1 |
| Shuban | 9.9 | 7.6 | 0 | 9.0 | 9.6 | 16.7 | 8.3 | 6.3 | 9.1 | 9.4 |
| Daal | 61.8 | 44.4 | 0 | 51.0 | 60.9 | 83.3 | 14.6 | 48.4 | 50.0 | 56.0 |
| Qandho | 36.4 | 20.1 | 50.0 | 22.2 | 37.1 | 50.0 | 6.3 | 37.5 | 12.1 | 29.0 |
| Madax | 49.0 | 31.1 | 0 | 38.4 | 49.7 | 83.3 | 18.8 | 35.9 | 40.9 | 43.4 |
| xanuun Joint | 33.0 | 18.8 | 0 | 23.0 | 31.0 | 33.3 | 16.7 | 20.3 | 19.7 | 27.7 |
| Lalabbo | 18.8 | 10.4 | 25.0 | 13.6 | 21.3 | 33.3 | 8.3 | 9.4 | 18.2 | 16.1 |
| finan | 2.3 | 0.7 | 0 | 1.9 | 2.5 | 0 | 4.2 | 1.6 | 1.5 | 2.1 |
| Matagid | 2.2 | 2.1 | 25.0 | 1.4 | 2.0 | 0 | 2.1 | 0 | 0 | 1.7 |
| Saamayn kasta oo caafimaad | 39.2 | 19.4 | 0 | 25.2 | 39.1 | 33.3 | 16.7 | 28.1 | 24.2 | 31.8 |
| Aan awoodin in uu qabto hawl maalmeed caadi ah | 35.2 | 18.1 | 0 | 22.1 | 33.0 | 33.3 | 10.4 | 25.0 | 15.2 | 28.3 |
| Aan shaqayn karin ama dugsi tegi karin | 13.7 | 4.9 | 0 | 9.0 | 21.3 | 16.7 | 10.4 | 6.3 | 13.6 | 11.3 |
| Daryeel caafimaad oo loo baahan yahay | 2.1 | 1.4 | 0 | 1.5 | 3.0 | 0 | 6.3 | 0 | 0 | 1.8 |
| Telehealth | 0.9 | 0.7 | 0 | 0.7 | 1.0 | 0 | 2.1 | 0 | 0 | 0.8 |
| Rugta caafimaadka | 0.7 | 0.7 | 0 | 0.6 | 0.5 | 0 | 4.2 | 0 | 0 | 0.6 |
| Booqasho degdeg ah | 0.2 | 0 | 0 | 0.2 | 0 | 0 | 4.2 | 0 | 0 | 0.2 |
| Isbitaaleynta | 0.05 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 |
XIGASHO. Dareen-celinta xun iyo saamaynta caafimaad ee ay soo sheegaan dadka qaatay 3 qiyaasood* Moderna (N = 6,283) ama Pfizer-BioNTech (N = 6,308) tallaalka COVID-19 oo dhammaystiray ugu yaraan hal sahan oo lagu hubinayey caafimaadka maalmaha 0- 7 qiyaas kasta ka dib, lambar lambar ahaan - Mareykanka, Ogosto 12 - Sebtember 19, 2021
MAXAA LAGU QAADAYAA MAQAALKAN:
- Results from a phase 3 clinical trial conducted by Pfizer-BioNTech that included 306 persons aged 18–55 years showed that adverse reactions after receipt of a third dose administered 5–8 months after completion of a 2-dose primary mRNA vaccination series were similar to those reported after receipt of dose 2.
- Persons who reported receiving a primary series from different manufacturers or a manufacturer that was unknown or unavailable in the United States, or 2 doses of vaccine after receipt of a Janssen (Johnson &.
- On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose after completion of a primary vaccination series to eligible persons with moderate to severe immunocompromising conditions (1,2).
